Abstract
American Journal of HematologyVolume 81, Issue 10 p. 798-799 Brief ReportFree Access A case of relapsed meningeal Burkitt's leukemia/lymphoma treated with intraventricular rituximab combined with high-dose cytarabine A. Billio, Corresponding Author A. Billio Department of Haematology and Bone Marrow Transplantation, Regional Hospital, S. Maurizio Bolzano, ItalyDepartment of Haematology and Bone Marrow Transplantation, Regional Hospital, S. Maurizio Bolzano, ItalySearch for more papers by this authorM. Svaldi, M. Svaldi Department of Haematology and Bone Marrow Transplantation, Regional Hospital, S. Maurizio Bolzano, ItalySearch for more papers by this authorE. Morello, E. Morello Department of Haematology and Bone Marrow Transplantation, Regional Hospital, S. Maurizio Bolzano, ItalySearch for more papers by this authorB. Amato, B. Amato Department of Haematology and Bone Marrow Transplantation, Regional Hospital, S. Maurizio Bolzano, ItalySearch for more papers by this authorP. Coser, P. Coser Department of Haematology and Bone Marrow Transplantation, Regional Hospital, S. Maurizio Bolzano, ItalySearch for more papers by this author A. Billio, Corresponding Author A. Billio Department of Haematology and Bone Marrow Transplantation, Regional Hospital, S. Maurizio Bolzano, ItalyDepartment of Haematology and Bone Marrow Transplantation, Regional Hospital, S. Maurizio Bolzano, ItalySearch for more papers by this authorM. Svaldi, M. Svaldi Department of Haematology and Bone Marrow Transplantation, Regional Hospital, S. Maurizio Bolzano, ItalySearch for more papers by this authorE. Morello, E. Morello Department of Haematology and Bone Marrow Transplantation, Regional Hospital, S. Maurizio Bolzano, ItalySearch for more papers by this authorB. Amato, B. Amato Department of Haematology and Bone Marrow Transplantation, Regional Hospital, S. Maurizio Bolzano, ItalySearch for more papers by this authorP. Coser, P. Coser Department of Haematology and Bone Marrow Transplantation, Regional Hospital, S. Maurizio Bolzano, ItalySearch for more papers by this author First published: 12 July 2006 https://doi.org/10.1002/ajh.20589Citations: 1AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL No abstract is available for this article. REFERENCES 1 Reiter A, Schrappe M, Tiemann M, et al. Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: a report of the Berlin–Frankfurt–Munster Group Trial NHL-BFM 90. Blood 1999;15; 94(10): 3294– 3306. 2 Boye J, Elter T, Engert A. An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab. Ann Oncol 2003; 14: 520– 535. 3 Harjunpaa A, Wiklund T, Collan J, Janes R, Rosenberg J, Lee D, Grillo-Lopez A, Meri S. Complement activation in circulation and central nervous system after rituximab (anti-CD20) treatment of B-cell lymphoma. Leuk Lymphoma 2001; 42: 731– 738. 4 Rubenstein JL, Combs D, Rosenberg J, Levy A, McDermott M, Damon L, Ignoffo R, Aldape K, Shen A, Lee D, Grillo-Lopez A, Shuman MA. Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment. Blood 2003;15; 101: 466– 468. 5 Schulz H, Pels H, Wolf I, Zeelen U, Germing U, Engert A. Intraventricular treatment of relapsed CNS lymphoma with the anti-CD20 antibody rituximab. Haematologica 2004; 89: 753– 754. Citing Literature Volume81, Issue10October 2006Pages 798-799 ReferencesRelatedInformation
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
